Capricor Therapeutics (NASDAQ:CAPR) Sees Large Volume Increase – Here’s Why

Posted by George Bondi on Aug 27th, 2026

Capricor Therapeutics, Inc. (NASDAQ:CAPR – Get Free Report) shares saw an uptick in trading volume on Thursday . 3,479,674 shares changed hands during trading, an increase of 17% from the previous session’s volume of 2,965,967 shares.The stock last traded at $10.4050 and had previously closed at $9.36.

Capricor Therapeutics News Summary

Here are the key news stories impacting Capricor Therapeutics this week:

Positive Sentiment: Oppenheimer upgraded Capricor to Outperform, providing a bullish Wall Street signal that may support the stock and partially counter ongoing legal concerns. Capricor Therapeutics Raised to Outperform at Oppenheimer
Neutral Sentiment: Unusually high call-option activity was reported on August 25, with 18,509 calls purchased—about 190% above typical volume. This may indicate bullish speculation or hedging, but it does not confirm a sustained share-price recovery.
Negative Sentiment: Multiple law firms are promoting a securities class action against Capricor and certain executives. The lawsuit alleges that management’s statements about the Phase 3 HOPE-3 trial failed to disclose changes to the study’s pre-specified statistical analysis plan that allegedly lacked FDA agreement. Plaintiffs claim the FDA later characterized related results as “post-hoc and exploratory.” The allegations have not been proven. SueWallSt Capricor securities class action deadline
Negative Sentiment: The repeated notices highlight a September 28, 2026 deadline for investors to seek lead-plaintiff status. Although the deadline itself does not create a direct financial liability, the volume of announcements reinforces concerns about potential litigation costs, management credibility, FDA compliance, and the commercial prospects of Capricor’s lead programs. Capricor class action lawsuit deadline
Negative Sentiment: Investor-rights firms also pointed to Capricor’s recent second-quarter earnings call, which reportedly omitted a management question-and-answer session with analysts. That unusual format may increase uncertainty around the company’s trial results, regulatory strategy, and response to the litigation. Capricor Q2 earnings and securities class action

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on CAPR. JonesTrading cut Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, July 31st. LADENBURG THALM/SH SH cut Capricor Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, July 30th. Wall Street Zen downgraded Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 1st. Piper Sandler downgraded Capricor Therapeutics from an “overweight” rating to a “neutral” rating and set a $2.00 target price on the stock. in a research report on Thursday, July 30th. Finally, HC Wainwright reissued a “neutral” rating on shares of Capricor Therapeutics in a report on Monday, July 27th. Two analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $29.15.

Read Our Latest Analysis on CAPR

Capricor Therapeutics Stock Up 9.8%

The firm has a market cap of $597.62 million, a price-to-earnings ratio of -4.19 and a beta of 0.54. The business has a 50 day moving average of $15.20 and a 200 day moving average of $24.51.

Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) last announced its earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.11). Research analysts predict that Capricor Therapeutics, Inc. will post -1.65 earnings per share for the current year.

Insider Buying and Selling at Capricor Therapeutics

In related news, CFO Anthony Bergmann sold 24,100 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $30.38, for a total transaction of $732,158.00. Following the transaction, the chief financial officer owned 11,223 shares of the company’s stock, valued at approximately $340,954.74. This represents a 68.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold a total of 25,000 shares of company stock valued at $759,158 over the last ninety days. Insiders own 9.20% of the company’s stock.

Institutional Trading of Capricor Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. lifted its stake in shares of Capricor Therapeutics by 122.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 2,786 shares during the period. ACT Capital Management LLC purchased a new stake in shares of Capricor Therapeutics in the fourth quarter valued at $43,000. KBC Group NV purchased a new stake in shares of Capricor Therapeutics in the first quarter valued at $44,000. Tower Research Capital LLC TRC increased its stake in Capricor Therapeutics by 280.8% in the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 4,976 shares during the last quarter. Finally, Regal Investment Advisors LLC acquired a new position in Capricor Therapeutics in the third quarter valued at $92,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

About Capricor Therapeutics

(Get Free Report)

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.